Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AARD Aardvark Therapeutics

Not Yet Opened 04-06 16:00:00 EDT

4.13

-0.17

-3.95%

盘后4.19

+0.06+1.45%

19:51 EDT

High4.39	Low4.04	Vol227.16K
Open4.30	D1 Closing4.30	Amplitude8.14%
Mkt Cap89.61M	Tradable Cap24.32M	Total Shares21.70M
T/O941.50K	T/O Rate3.86%	Tradable Shares5.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":4.13,"timestamp":1775505600000,"preClose":4.3,"halted":0,"volume":227161,"hourTrading":{"tag":"盘后","latestPrice":4.19,"preClose":4.13,"latestTime":"19:51 EDT","volume":1983,"amount":8215.73,"timestamp":1775519498742,"change":0.06,"changeRate":0.014528,"amplitude":0.026634},"delay":0,"changeRate":-0.03953488372093022,"floatShares":5888000,"shares":21696893,"eps":-2.6398466,"marketStatus":"Not Yet Opened","change":-0.17,"latestTime":"04-06 16:00:00 EDT","open":4.3,"high":4.39,"low":4.04,"amount":941503.065811,"amplitude":0.081395,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.6398466,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775548800000},"marketStatusCode":0,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":4.3,"preHourTrading":{"tag":"盘前","latestPrice":4.39,"preClose":4.3,"latestTime":"09:22 EDT","volume":1574,"amount":6833.130647999999,"timestamp":1775481745066,"change":0.09,"changeRate":0.02093,"amplitude":0.030233},"postHourTrading":{"tag":"盘后","latestPrice":4.19,"preClose":4.13,"latestTime":"19:51 EDT","volume":1983,"amount":8215.73,"timestamp":1775519498742,"change":0.06,"changeRate":0.014528,"amplitude":0.026634},"volumeRatio":0.835145,"impliedVol":0.3708,"impliedVolPercentile":0.0392},"requestUrl":"/m/hq/s/AARD/wiki","defaultTab":"wiki","newsList":[{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","ELVN","ABSI","AMZN","AVTX","CVX","ARE","MTDR","CNM","AZYY","CEG","AMZP","AIR","USAW.SI","BAM","FANG","DK","CALM","CEGX","DINO","KBH","BP","AARD","AMZU","FRPT","FIGG","AVAH","BWXT","CDE","FIG","BXP","BZAI","GLW","EVGO","BRZE","HD","CVI","BCAX","ACAD","ADUS","ESE","BTM","DG","AMZD","HAL","AFG","APEI","BPH","INSM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621206244","title":"Aardvark Therapeutics Inc : B. Riley Cuts Target Price to $8 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2621206244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621206244?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:40","pubTimestamp":1774356009,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062681","title":"B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062681?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:30","pubTimestamp":1774355441,"startTime":"0","endTime":"0","summary":"B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061633","title":"RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061633?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:36","pubTimestamp":1774352171,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Hold rating on Aardvark Therapeutics, Inc. yesterday and set a price target of $6.00. The company’s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069396","title":"Aardvark Therapeutics Price Target Maintained With a $9.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069396?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:09","pubTimestamp":1774350540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 07:09 ET (11:09 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621065739","title":"Aardvark Therapeutics Establishes $150 Million Equity Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2621065739","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621065739?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:37","pubTimestamp":1774348644,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. ( ($AARD) ) has shared an announcement. On March 23, 2026, Aardvark Therapeutics, Inc. entered into an equity distribut...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-establishes-150-million-equity-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-establishes-150-million-equity-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","AARD","BK4215","BK4007","BK4588","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621789063","title":"Aardvark Therapeutics Inc - Enters Equity Distribution Agreement With Piper Sandler on March 23, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621789063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621789063?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:10","pubTimestamp":1774347027,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C03N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063783","title":"Aardvark Therapeutics Inc - May Offer Shares up to $150 Mln Aggregate Offering Price - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063783?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:10","pubTimestamp":1774347027,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C03N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063186","title":"Aardvark Therapeutics signs equity distribution agreement for up to USD 150 million offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063186","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063186?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:02","pubTimestamp":1774346552,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics entered into an equity distribution agreement with Piper Sandler to sell shares of its common stock from time to time.The program allows sales of up to USD 150.0 million in aggregate offering price under the company’s shelf registration statement.Piper Sandler will receive a 3% commission on the gross sales price per share sold under the agreement.The company is not obligated to sell any shares under the arrangement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5CrwhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","AARD","LU0053671581.USD","BK4007","PIPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087042","title":"Aardvark pauses two obesity drug trials as it reviews side effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087042?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:52","pubTimestamp":1774302726,"startTime":"0","endTime":"0","summary":"March 23  - Aardvark Therapeutics AARD.O said on Monday it has voluntarily paused two mid-stage studies testing its experimental combination treatment for obesity as it reviews side effects associated with one of the drugs.The combination treatment, ARD-201, was being tested to induce weight loss and prevent weight regain among patients who have lost about 15% of body weight on the popular GLP-1 class of drugs, which includes Eli Lilly's LLY.N Zepbound and Novo Nordisk's NOVOb.CO Wegovy.ARD-201 is a combination of Aardvark's experimental drug, ARD-101, and Merck's diabetes drug MRK.N Januvia, chemically known as sitagliptin.ARD-101 is designed to trigger the release of multiple gut-peptide hormones, including GLP-1, to regulate hunger.Last month, the company identified heart-related side effects during safety monitoring of ARD-101 in a healthy-volunteer study. It then paused a late-stage trial testing ARD-101 in patients with a rare genetic disorder called Prader-Willi syndrome.Aardvar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL4N40B1W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0689472784.USD","IE0009355771.USD","LU1868837300.USD","LU0786609619.USD","SG9999001176.SGD","IE00BJT1NW94.SGD","LU1720051017.SGD","LU0385154629.USD","LU2461242641.AUD","SG9999014542.SGD","LU1868836757.USD","LU0985320562.USD","LU1868837136.USD","LU2265009873.SGD","SG9999018865.SGD","LU0823416689.USD","LU0648001328.SGD","LU1069344957.HKD","LU2471134879.HKD","IE00BJLML261.HKD","BK4534","LU0640476718.USD","LU0683600562.USD","SG9999017495.SGD","LU0225283273.USD","SG9999001176.USD","LU1162221912.USD","LU1868836914.USD","SGXZ81514606.USD","LU2168564149.EUR","LU2746668974.SGD","BK4588","BK4550","LU2271345857.HKD","LU2552382058.USD","IE00BWXC8680.SGD","LU2360106947.USD","SG9999001440.SGD","LU2089984988.USD","LU0265550946.USD","LU2468319806.SGD","LU2324357040.USD","LU2552382132.HKD","LU2087625088.SGD","LU0320765059.SGD","LU0820562030.AUD","LU1585245621.USD","LU2168564065.EUR","IE00BSNM7G36.USD","LU0234572021.USD","LU0354030438.USD","IE00BBT3K403.USD","LU0238689110.USD","LU0323591593.USD","LU2237443978.SGD","LU2456880835.USD","LU1934455277.USD","LU1868836591.USD","LU0432979614.USD","LU0882574055.USD","LU0114720955.EUR","LU0203345920.USD","LU2750360641.GBP","LU0211331839.USD","IE00BK4W5M84.HKD","IE0002141913.USD","LU2023250504.SGD","SG9999014914.USD","SGXZ51526630.SGD","LU0097036916.USD","LU2746668461.USD","LU0820561818.USD","LU2471134523.USD","LU1551013425.SGD","BK4581","LU2237443895.HKD","LU1035773651.USD","IE000M9KFDE8.USD","LU1712237335.SGD","LU1571399168.USD","IE0001KFT4U8.USD","LU1057294990.SGD","LU2125154778.USD","LU2491049909.HKD","LU1064131342.USD","LU1066051498.USD","LU0265550359.USD","LU1127390331.HKD","IE00BJJMRZ35.SGD","LU2168564495.EUR","LU2361044865.SGD","LU1037948897.HKD","IE00BN29S564.USD","LU2112291526.USD","BK4533","LU2237438978.USD","LU0058720904.USD","LU0256863811.USD","IE00B4JS1V06.HKD","LU0210536198.USD","LU2023250330.USD","SG9999002232.USD","LU1267930730.SGD","LU0006306889.USD","LU0787776722.HKD","LU0823434740.USD","LU1066051811.HKD","LU1061106388.HKD","LU0320765489.SGD","LU0122379950.USD","IE00B2B36J28.USD","LLYZ","IE00B1XK9C88.USD","LU2111349929.HKD","SGXZ57979304.SGD","BK4516","IE00BKDWB100.SGD","LU0098860793.USD","LU1623119135.USD","IE0004445015.USD","LU0965509283.SGD","LU0256863902.USD","LU0882574139.USD","AARD","LU1366192091.USD","LU2236285917.USD","LU2361045086.USD","LU0106261372.USD","LU2417539215.USD","IE00B4R5TH58.HKD","GB00BDT5M118.USD","IE00B1BXHZ80.USD","IE00BJJMRX11.SGD","LU2264538146.SGD","LU0079474960.USD","LU0868494708.USD","LU2750360997.AUD","IE00BLSP4452.SGD","LU0109394709.USD","LU0820561909.HKD","LU1934455194.USD","LU2023250843.SGD","LU2213496289.HKD","LU0109391861.USD","LU0320765992.SGD","LU2108987350.USD","LU2462157665.USD","LU0320765646.SGD","LU0208291251.USD","LU0203347892.USD","LU0868494617.USD","LU1035775433.USD","BK4585","LU0070302665.USD","LU0096364046.USD","LU0130517989.USD","LU1023059063.AUD","LU2237443465.HKD","LU2361044949.HKD","LU2168563687.JPY","LU1917777945.USD","LU0943347566.SGD","LU2211815571.USD","LU0158827781.USD","LU1069347547.HKD","LU2357305700.SGD","LU1291159041.SGD","LU2756315664.SGD","SG9999002224.SGD","LU0942090050.USD","LU2063271972.USD","LU1814569148.SGD","LU1280957306.USD","IE00BFTCPJ56.SGD","LU0094547139.USD","LU1629891620.HKD","LU0266013472.USD","SG9999015358.SGD","LU0316494557.USD","LU0354030511.USD","LU2756315318.SGD","LU1989771016.USD","LLYX","IE00BLSP4239.USD","IE0005OL40V9.USD","LU2237443622.USD","SG9999014575.USD","SGXZ99366536.SGD","LU1430594728.SGD","LU2360032135.SGD","LU1699723380.USD","LU2471134796.USD","SG9999018857.SGD","LU2106854487.HKD","ELIL","LLII","BK4007","IE00BJJMRY28.SGD","LU1983299246.USD","LU2552382215.SGD","LU0889565916.HKD","LU1037948541.HKD","LU2028103732.USD","LU0965508806.USD","LU1941712264.USD","LU0456855351.SGD","LU1720051108.HKD","SG9999014906.USD","SG9999015945.SGD","LU0203202063.USD","LU0158827948.USD","LU1066051225.USD","BK4599","IE0004445239.USD","LU1548497426.USD","LU2089283258.USD","LU1066053197.SGD","IE00BK4W5L77.USD","LU1093756325.SGD","LU2237443382.USD","LU1941712348.USD","LU1989772840.SGD","LU0061475181.USD","IE00BN8TJ469.HKD","IE00BFSS8Q28.SGD","LU1201861249.SGD","LU1093756168.USD","LU2023251221.USD","LU0203201768.USD","LU2237443549.SGD","LU0198837287.USD","SG9999015978.USD","LU0130102774.USD","LU0471298777.SGD","LU0861579265.USD","LU2491050154.USD","SG9999015986.USD","LU0353189680.USD","LU0353189763.USD","LU0471298694.HKD","LU0672654240.SGD","SG9999015952.SGD","IE00B775H168.HKD","LU0466842654.USD","LU2125154935.USD","SG9999014567.USD","LU1974910355.USD","IE00B7KXQ091.USD","LU2896262040.SGD","LU0417517546.SGD","LU2089284900.SGD","SGXZ31699556.SGD","LU1232071149.USD","ELIS","LU0823434583.USD","LU1988902786.USD","LU0289739699.SGD","LU1934455863.HKD","SG9999014880.SGD","IE00BFSS7M15.SGD","LU1116320901.HKD","SG9999015341.SGD","LU1804176565.USD","LU2168564222.USD","LU2471134952.CNY","BK4559","SG9999014559.SGD","IE00BKPKM429.USD","LU0708995401.HKD","LU0965509101.SGD","LU1323610961.USD","LU2602419157.SGD","LU0477156953.USD","LU2491050071.SGD","LU1989772923.USD","LU0980610538.SGD","SG9999013999.USD","LU0965509010.AUD","LU1116320737.USD","LU0964807845.USD","LU1145028129.USD","SG9999014898.SGD","LU1929549753.HKD","LU1551013342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621499087","title":"Aardvark Therapeutics Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621499087","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621499087?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:34","pubTimestamp":1774301669,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics  filed a shelf registration statement on Monday with the US Securities and Exchange Commission for the potential sale of up to $400 million in securities.The filing covers common and preferred stock, debt securities, warrants, rights, units, and depositary shares.Net proceeds will be used for general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087537","title":"Aardvark Therapeutics files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087537?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:15","pubTimestamp":1774300511,"startTime":"0","endTime":"0","summary":"17:11 EDT Aardvark Therapeutics (AARD) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087807","title":"Aardvark files USD 400 million shelf registration for common stock and debt securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087807","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087807?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:11","pubTimestamp":1774300305,"startTime":"0","endTime":"0","summary":"Aardvark reported progress around its lead candidate ARD-101, which is being developed for hyperphagia associated with Prader-Willi Syndrome and is positioned as a potential treatment option in an area with limited alternatives.The company said it voluntarily paused enrollment and dosing in the Phase 3 HERO and related open-label extension trials after reversible cardiac observations in a healthy volunteer study, a development that could affect timelines and near-term competitive positioning.Separately, Aardvark filed for a shelf registration covering up to USD 400.0 million of securities, including an at-the-market program of up to USD 150.0 million, which could provide financing flexibility while clinical plans are reviewed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5SFfRg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087809","title":"Aardvark Therapeutics Inc - May Offer up to $400 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087809?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:11","pubTimestamp":1774300276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621845600","title":"Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621845600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621845600?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:16","pubTimestamp":1774297012,"startTime":"0","endTime":"0","summary":"As of December 31, 2025, Aardvark had cash, cash equivalents and short-term investments of $110M, compared to $73.7M as of December 31, 2024. Based...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-reports-q4-eps-81c-consensus-83c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-reports-q4-eps-81c-consensus-83c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084871","title":"Aardvark Therapeutics reports lower-than-expected 2025 net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084871?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:16","pubTimestamp":1774296993,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics reports lower-than-expected 2025 net lossOverviewUS biopharmaceutical firm's 2025 net loss slightly beat analyst expectationsOutlookAardvark expects to provide further guidance o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL1N40B13H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621608125","title":"Aardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621608125","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621608125?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:07","pubTimestamp":1774296439,"startTime":"0","endTime":"0","summary":"Aardvark published a press release reporting fourth-quarter and full-year 2025 financial results, and said it had USD 110.0 million in cash, cash equivalents and short-term investments as of Dec. 31, 2025.Net loss was USD 17.6 million and net loss per share was USD 0.81 for Q4 2025.R&D expense rose 77.4% to USD 14.3 million in Q4 2025, while G&A expense more than doubled to USD 4.4 million.Management said the Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome and the ARD-201 obesity program were voluntarily paused after reversible cardiac QRS prolongation was observed in healthy-volunteer studies, with further guidance expected in Q2 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8c54RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014039.USD","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","LU2210150020.SGD","BK4588","BK4112","NDAQ","SG9999014021.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4007","IE00BN0W2V16.EUR","AARD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621405081","title":"Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621405081","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621405081?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:06","pubTimestamp":1774296385,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.91) by 11.09 percent. This is a 62.5 percent increase over losses of $(2.16) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51419139/aardvark-therapeutics-q4-eps-0-81-beats-0-91-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621558084","title":"Aardvark Therapeutics:  Pauses Ard-201 Obesity Program Including Power and Strength Trials; Further Guidance Expected Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621558084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621558084?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nPLX25DBD7:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621308455","title":"Aardvark Therapeutics: Pauses Phase 3 Hero and Ole Trials for Ard-101 in Pws; Further Guidance Expected Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621308455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621308455?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nPLX25DBD7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://aardvarktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1346},{"period":"1month","weight":-0.294},{"period":"3month","weight":-0.6897},{"period":"6month","weight":-0.7589},{"period":"1year","weight":-0.4939},{"period":"ytd","weight":-0.6853}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Aardvark Therapeutics","nameEN":"Aardvark Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aardvark Therapeutics(AARD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aardvark Therapeutics,AARD,Aardvark Therapeutics股票,Aardvark Therapeutics股票老虎,Aardvark Therapeutics股票老虎国际,Aardvark Therapeutics行情,Aardvark Therapeutics股票行情,Aardvark Therapeutics股价,Aardvark Therapeutics股市,Aardvark Therapeutics股票价格,Aardvark Therapeutics股票交易,Aardvark Therapeutics股票购买,Aardvark Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aardvark Therapeutics(AARD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}